Pediatric Underdosing of Efavirenz: A Pharmacokinetic Study in Uganda

被引:29
作者
Fillekes, Quirine [1 ]
Natukunda, Eva [2 ]
Balungi, Jackie [3 ]
Kendall, Lindsay [6 ]
Bwakura-Dangarembizi, Mutsa [4 ]
Keishanyu, Rosette [2 ]
Ferrier, Alex [6 ]
Lutakome, Joseph [5 ]
Gibb, Diana M. [6 ]
Burger, David M. [1 ]
Walker, A. Sarah [6 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Pharm, NL-6525 GA Nijmegen, Netherlands
[2] Joint Clin Res Ctr, Kampala, Uganda
[3] Pediat Infect Dis Ctr, Mulago, Uganda
[4] Univ Zimbabwe, Sch Med, Dept Paediat & Child Hlth, Harare, Zimbabwe
[5] MRC UVRI Uganda Res Unit AIDS, Entebbe, Uganda
[6] MRC Clin Trials Unit, London, England
基金
英国医学研究理事会;
关键词
children; efavirenz; HIV-1; pharmacokinetics; Uganda; HIV-1-INFECTED CHILDREN; ANTIRETROVIRAL THERAPY; HIGH PREVALENCE; CYP2B6; POLYMORPHISM; LAMIVUDINE; TRIAL; INDINAVIR; VARIANTS; WEIGHT;
D O I
10.1097/QAI.0b013e318235e560
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To evaluate international pediatric efavirenz dosing recommendations using full pharmacokinetic (PK) information. Design: Open-label, multicenter, PK study. Methods: Forty-one HIV-infected Ugandan children (3-12 years) on efavirenz + lamivudine + abacavir were enrolled in a study of twice-daily to once-daily lamivudine + abacavir 36 weeks after antiretroviral therapy initiation in the ARROW trial. Once-daily efavirenz doses were 200, 250, 300, 350 mg for children weighing 10 to <15, 15 to <20, 20 to <25, 25 to <30 kg, respectively, using 200/50 mg capsules or halved 600 mg tablets in case of 300 and 350 mg doses. Intensive plasma PK sampling (t = 0, 1, 2, 4, 6, 8, 12 hours postobserved ingestion) was performed at steady state (PK1) and repeated 4 weeks later (PK2, including a further 24-hour sample). Results: Forty-one and 39 children had evaluable efavirenz profiles at PK1 and PK2, respectively. Seventeen (41%) were boys. Five, 16, 17, 3 were in the 10 to <15, 15 to <20, 20 to <25, 25 to <30 kg weight bands. The geometric mean (%CV) the area under the concentration-time curve 0-24 hours postdose was 50.8 (90.8%) and 55.5 (82.7%) h.mg.L-1 at PK1 and PK2, respectively. Six children at PK1 and 7 at PK2 had subtherapeutic C-8h and/or C-12h (<1.0 mg/L), 7 of 41 (17%) at either visit. At PK2, 15 of 39 (38%) children had C-24h <1.0 mg/L (median (interquartile range) [range] 1.1 (0.7-2.9) [0.3-18.4]). Ten children at PK1 and 11 at PK2 had C-8h and/or C-12h >4.0 mg/L; 12 of 41 (29%) at either visit. Conclusions: African children aged 3-12 years, on efavirenz dosed according to 2006 WHO/manufacturer's recommendations, had lower and highly variable efavirenz PK parameters compared with adult data from manufacturer's leaflet. There were no differences across weight bands, suggesting no major effect of using half tablets. Higher pediatric efavirenz doses, as per WHO 2010 recommendations, should be used and investigated further but may risk increasing the proportion of children with potentially toxic levels.
引用
收藏
页码:392 / 398
页数:7
相关论文
共 24 条
[1]   The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers [J].
Aarnoutse, RE ;
Grintjes, KJT ;
Telgt, DSC ;
Stek, M ;
Hugen, PWH ;
Reiss, P ;
Koopmans, PP ;
Hekster, YA ;
Burger, DM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (01) :57-67
[2]  
CAPPARELLI E, 2009, 16 C RETROVIRUSES OP
[3]  
Cole TJ, 1998, STAT MED, V17, P407, DOI 10.1002/(SICI)1097-0258(19980228)17:4<407::AID-SIM742>3.0.CO
[4]  
2-L
[5]   Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial [J].
Fletcher, C. V. ;
Brundage, R. C. ;
Fenton, T. ;
Alvero, C. G. ;
Powell, C. ;
Mofenson, L. M. ;
Spector, S. A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) :300-306
[6]  
Haas DW, 2004, AIDS, V18, P2391
[7]   Is the Recommended Dose of Efavirenz Optimal in Young West African Human Immunodeficiency Virus-Infected Children? [J].
Hirt, Deborah ;
Urien, Saik ;
Olivier, Mathieu ;
Peyriere, Helene ;
Nacro, Boubacar ;
Diagbouga, Serge ;
Zoure, Emmanuelle ;
Rouet, Francois ;
Hien, Herve ;
Msellati, Philippe ;
Van De Perre, Philippe ;
Treluyer, Jean-Marc .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (10) :4407-4413
[8]   Genetic variability of CYP2B6 in populations of African and Asian origin:: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz [J].
Klein, K ;
Lang, T ;
Saussele, T ;
Barbosa-Sicard, E ;
Schunck, WH ;
Eichelbaum, M ;
Schwab, M ;
Schwab, M ;
Zanger, UM .
PHARMACOGENETICS AND GENOMICS, 2005, 15 (12) :861-873
[9]   Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver [J].
Lang, T ;
Klein, K ;
Fischer, J ;
Nüssler, AK ;
Neuhaus, P ;
Hofmann, U ;
Eichelbaum, M ;
Schwab, M ;
Zanger, UM .
PHARMACOGENETICS, 2001, 11 (05) :399-415
[10]   CYP2B6 Variants and Plasma Efavirenz Concentrations during Antiretroviral Therapy in Port-au-Prince, Haiti [J].
Leger, Paul ;
Dillingham, Rebecca ;
Beauharnais, Carole Anne ;
Kashuba, Angela D. M. ;
Rezk, Naser L. ;
Fitzgerald, Daniel W. ;
Pape, Jean William ;
Haas, David W. .
JOURNAL OF INFECTIOUS DISEASES, 2009, 200 (06) :955-964